Appendix S: Information to facilitate discussion of risks and benefits of treatments for people with psoriasis

Data are provided for the proportions of people achieving remission, withdrawing due to adverse events and experiencing specific adverse events (as prioritised by the GDG) for interventions that have been recommended in this guideline. Data are based on pooled estimates where possible and from trials with populations and dosing appropriate to the intervention. For full details of the duration of treatment and dosing schedules please refer to the main text of the guideline.

Text is in grey when the GDG had very low confidence in the absolute estimates, for example due to confounding and inadequate sample size.

S.1 Topical therapies (short term)

Intervention	**Population – psoriasis phenotype**	**N achieving remission (clear/nearly clear or PASI75)**			**N experiencing:**					
					Withdrawal due to drug toxicity			**Serious/named adverse events**		
		Intervention	Placebo	Active comparator †	Intervention	Placebo	Active comparator †	Intervention	Placebo	Active comparator †
Vitamin D or vitamin D analogues	Chronic plaque psoriasis of trunk and limbs	OD: 220/1000 BD: 487/1000	OD: 7.6/100 BD: 122/1000	-	OD or BD: 23/1000	OD or BD: 29/1000	-	**Skin atrophy** BD: 1.9/1000	**Skin atrophy** BD: 3.2/1000	-
	Children with chronic plaque psoriasis of trunk and limbs	BD:605/1000	BD:441/1000	-	NA	NA	-	NA	NA	NA
	Scalp psoriasis	OD: 387/1000	OD: 219/1000	-	OD: 81/1000	OD: 52/1000	-	NA	NA	NA
Potent corticosteroids	Chronic plaque psoriasis of trunk and limbs	OD or BD: 394/1000	OD or BD: 77/1000	-	OD: 10/1000 BD: 25/1000	OD: 79/1000 BD: 0/1000	-	**Skin atrophy** OD or BD: 5.5/1000	**Skin atrophy** OD or BD: 0/1000	-

Intervention	Population –	N achieving remission (clear/nearly clear			N experiencing:					
	Scalp psoriasis	OD: 632/1000	OD: 223/1000	-	OD: 9.5/1000	OD: 41/1000	-	NA	NA	NA
Vitamin D or analogue and potent steroid, applied one in the morning and one in the evening	Chronic plaque psoriasis of trunk and limbs	611/1000	NA	Calcipotriol BD 469/1000	13/1000	NA	Calcipotriol BD: 26/1000	NA	NA	NA
Combined vitamin D or analogue and potent steroid	Chronic plaque psoriasis of trunk and limbs	OD: 494/1000	NA	Vit D OD: 193/1000	OD: 7.5/1000	NA	Vit D OD or BD: 27/1000	**Skin atrophy** OD: 4.2/1000	NA	**Skin atrophy** Vit D OD: 1.8/1000
	Scalp psoriasis	OD: 800/1000	OD: 500/1000	-	OD: 17/1000	OD: 0/1000	-	NA	NA	-
Very potent corticosteroids	Chronic plaque psoriasis of trunk and limbs	OD or BD: 625/1000	OD or BD: 13. 1/1000	-	OD or BD: 4.6/1000	OD or BD: 6.0/1000	-	**Skin atrophy** OD or BD: 23/1000	**Skin atrophy** OD or BD: 0/1000	-
	Scalp psoriasis	OD or BD: 646/1000	OD or BD: 80/1000	-	OD or BD: 0/1000	OD or BD: 5.9/1000	-	NA	NA	-
Tazarotene	Chronic plaque psoriasis of trunk and limbs	OD: 58/1000	OD: 20/1000	-	OD: 107/1000	OD: 44/1000	-	**Skin atrophy**: OD: 0/1000	**Skin atrophy** OD: 0/1000	-
Short-contact dithranol*	Chronic plaque psoriasis of trunk and limbs	OD: 430/1000	NA	Calcipotriol BD: 588/1000	OD: 82/1000	NA	Calcipotriol BD: 39/1000	NA	NA	NA
Coal tar	Chronic plaque psoriasis of trunk and limbs	OD: 111/1000 to 519/1000	NA	Calcipotriol BD: 214/1000 to	0-56/1000 depending on	NA	Calcipotriol BD: 0-40/1000	NA	NA	NA

Intervention	Population –	N achieving remission (clear/nearly clear			N experiencing:					
		depending on formulation and follow-up		723/1000	formulation and follow-up		depending on formulation and follow-up			
Tacrolimus	Psoriasis of the face and flexures	BD: 652/1000	BD: 309/1000	-	BD: 0/1000	BD: 25/1000	-	NA	NA	-
Pimecrolimus	Psoriasis of the flexures	BD: 714/1000	BD: 207/1000	-	BD: 0/1000	BD: 0/1000	-	**Skin atrophy** BD: 0/1000	**Skin atrophy** BD: 0/1000	-

[†] *An active comparator will only be included if no placebo comparison is available; the standard intervention will be chosen if multiple active comparators are available*

NA: Not available

-: Active comparison not reported as placebo comparison was available

**2/3 studies reported home-use of dithranol and in 1/3 studies the setting was unclear*

OD: Once daily

BD: Twice daily

S.2 Phototherapy (short-term)

Intervention	Population – psoriasis phenotype	N achieving remission (clear/nearly clear or PASI75)			N experiencing:					
					Withdrawal due to drug toxicity			Serious/named adverse events		
		Intervention	Placebo	Active comparator †	Intervention	Placebo	Active comparator †	Intervention	Placebo	Active comparator †
NBUVB vs PUVA	Plaque psoriasis	Twice weekly 647/1000	NA	Oral PUVA (twice weekly) 915/1000	Twice weekly 38/1000	NA	Oral PUVA (twice weekly) 47/1000	NA	NA	NA
PUVA (oral)	Palmoplantar pustulosis	3-4 times weekly 941/1000	No treatment 500/1000	-	3-4 times weekly 29/1000	No treatment 0/1000	-	**Burn** 3-4 times weekly 147/1000	**Burn** No treatment 0/1000	-
PUVA (cream)	Palmoplantar pustulosis	3 times weekly 952/1000	NA	NBUVB 3 times weekly 429/1000	3 times weekly 45/1000	NA	NBUVB 3 times weekly 0/1000	NA	NA	NA
NBUVB + vitamin D or analogues	Plaque psoriasis	3 times weekly 900/1000	NA	3 times weekly 611/1000	3 times weekly NBUVB alone 50/1000	NA	3 times weekly 28/1000	**Burn** 3 times weekly 200/1000	NA	**Burn** 3 times weekly NBUVB alone 111/1000
BBUVB + vitamin D or analogues	Plaque psoriasis	8 weeks 449/1000	NA	BBUVB alone 208/1000	41/1000	NA	BBUVB alone 19/1000	NA	NA	NA
Liquor carbonic distillate (equivalent 2.3% coal tar)	Plaque psoriasis	Clear (3x weekly UV) 583/1000	NA	NBUVB alone 3 times weekly	3 times weekly UV 0/1000	NA	NBUVB alone 3x weekly UV	**Burn** 3 times weekly UV)	NA	**Burn** NBUVB alone times

Intervention	Population –	N achieving remission (clear/nearly clear			N experiencing:					
plus NBUVB				500/1000			0/1000	167/1000		weekly 167/1000
Dithranol plus BBUVB	Psoriasis	625/1000	NA	BBUVB alone 458/1000	NA	NA	NA	NA	NA	NA

[†] *An active comparator will only be included if no placebo comparison is available; the standard intervention will be chosen if multiple active comparators are available*

NA: Not available

-: Active comparison not reported as placebo comparison was available

BBUVB: Broadband UVB

NBUVB: Narrow band UVB

PUVA: Psoralen plus UVA

S.3 Systemic, non-biologic therapies (short term)

Intervention	Population – psoriasis phenotype	N achieving remission (clear/nearly clear or PASI75)		N experiencing:			
				Withdrawal due to drug toxicity		Serious/named adverse events	
		Intervention	Placebo	Intervention	Placebo	Intervention	Placebo
Methotrexate; incremental dosing (+folic acid)	Chronic plaque psoriasis	415/1000	188/1000	55/1000	20/1000	**Elevated liver enzymes (>1.5-2.5 ULN)** 91/1000	**Elevated liver enzymes (>1.5-2.5 ULN)** 75/1000
Ciclosporin	Chronic plaque psoriasis	2.5-3 mg 232/1000 5 mg 600/1000	44/1000	0/1000	0/1000	**Hypertension** 391/1000 **Decrease in GFR >15%** 3 mg/kg: 333/1000 5 mg/kg: 500/1000	**Hypertension** 333/1000 **Decrease in GFR >15%** 0/1000
	Palmoplantar pustulosis	652/1000	200/1000	NA	NA	**Hypertension** 37/1000	**Hypertension** 0/1000
Acitretin – 25 mg	Plaque, pustular and erythrodermic psoriasis	480/1000	188/1000	18/1000	0/1000	**Cheilitis** 850/1000 **Hair loss** 150/1000 **Elevated liver enzymes (>ULN)** 200/1000 **Elevated cholesterol (>ULN)** 0/1000	**Cheilitis** 300/1000 **Hair loss** 100/1000 **Elevated liver enzymes (>ULN)** 0/1000 **Elevated cholesterol (>ULN)** 53/1000

GFR: Glomerular filtration rate

NA: Not available

ULN: Upper limit of normal

S.4 Systemic, biologic therapies (short term)

Intervention	Population – psoriasis phenotype	Prior biologics received	N achieving remission (clear/nearly clear or PASI75)			N experiencing: Withdrawal due to drug toxicity or serious adverse events		
			Intervention	Placebo	Active comparator†	Intervention	Placebo	Active comparator†
Infliximab	Adults with severe plaque psoriasis and prior biologic exposure	Unclear	723/1000	0/1000	-	NA	NA	NA
Etanercept	Adults with severe plaque psoriasis and prior biologic exposure	Included etanercept, alefacept, efalizumab, infliximab, and adalimumab (proportions unclear)	370/1000	NA	Ustekinumab 556/1000	NA	NA	NA
Ustekinumab	Adults with severe plaque psoriasis and prior biologic exposure	Included etanercept, alefacept, efalizumab, infliximab, and adalimumab (proportions unclear)	619/1000	170/1000	-	NA	NA	NA
Adalimumab	Adults with severe plaque psoriasis	Etanercept (32.1%), alefacept (23.1%), ustekinumab (23.1%), efalizumab (21.8%), infliximab (20.5%), and other (17.9%)	654/1000	NA	No prior biologic 744/1000	NA	NA	NA

† *An active comparator will only be included if no placebo comparison is available; the standard intervention will be chosen if multiple active comparators are available*

NA: Not available

-: Active comparison not reported as placebo comparison was available

S.5 Long-term risks

Intervention	Outcome(s)	Population – psoriasis phenotype	Number experiencing event
PUVA (oral)	Skin cancer – SCC	Plaque (84%), guttate (12%) and erythrodermic (4%) psoriasis	**Relative risk compared with the general population** **PUVA exposures RR** <100 5.1 (3.5-7.2) 100-159 8.4 (5.6-12.1) 160-336 26.5 (22.2-31.4) ≥337 68.5 (54.9-84.5) **Absolute increase in risk** **PUVA exposures SCCs % increase in 10-year risk** <100 18 **1.7%** 100-159 15 **2.7%** 160-336 68 **8.8 %** ≥337 34 **12.7%**
NBUVB	Skin cancer	Insufficient data available	
Methotrexate	Liver fibrosis, bone marrow suppression and pneumonitis	No long-term data available	
Ciclosporin	Hypertension, renal impairment, gout and hyperuricaemia	No long-term data available	
Acitretin	Hyperlipidaemia, hepatotoxicity, skeletal AEs and cheilitis	No long-term data available	

PUVA: Psoralen plus UVA

RR: Relative risk

SCC: Squamous cell carcinoma